Company intelligence / Profile preview
OncoC4
Rockville, Maryland, USAoncoc4.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
OncoC4’s lead candidate ONC‑392/gotistobart has advanced to late-stage clinical trials for solid tumors. The company has a strategic partnership with BioNTech for co-development and commercialization of ONC‑392. Early data suggest the approach may enhance anti-tumor activity while reducing autoimmune side effects compared to earlier CTLA‑4 inhibitors. Additional programs are advancing through preclinical and early clinical development targeting novel pathways such as PD‑1/VEGF bispecifics and Siglec agonists.
- Therapeutic areas
- OncologyNeurology
- Modalities
- monoclonal antibodies (mAbs)bispecific antibodies (BsAbs)antibody-drug conjugates (ADCs)CAR T-cell therapies
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
03
Partnerships
BioNTech – exclusive worldwide license/co-development agreement for ONC–392/BNT316 ($200M upfront plus milestones & royalties)
Beyond the preview
Go deeper on OncoC4.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OncoC4.